Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Alternative routes for tranexamic acid treatment in obstetric bleeding (WOMAN-PharmacoTXA trial): a randomised trial and pharmacological study in caesarean section births.

Title: Alternative routes for tranexamic acid treatment in obstetric bleeding (WOMAN-PharmacoTXA trial): a randomised trial and pharmacological study in caesarean section births.
Authors: Shakur-Still, Haleema; Roberts, Ian; Grassin-Delyle, Stanislas; Chaudhri, Rizwana; Geer, Amber; Arribas, Monica; Lamy, Elodie; Mansukhani, Raoul; Lubeya, Mwansa Ketty; Javaid, Kiran; Kayani, Aasia; Israr, Naila; Mazhar, Syeda Batool; Urien, Saïk; Bouazza, Naïm; Foissac, Frantz; Prowse, Danielle; Carrington, Laura; Barrow, Collette; Onandia, Julio Gil; Balogun, Eni
Publisher Information: Wiley
Publication Year: 2023
Collection: London School of Hygiene & Tropical Medicine: LSHTM Research Online
Description: OBJECTIVE: To examine the safety, efficacy and pharmacology of intravenous (IV), intramuscular (IM) and oral tranexamic acid (TXA) use in pregnant women. DESIGN: Randomised, open-label trial. SETTING: Hospitals in Pakistan and Zambia. POPULATION: Women giving birth by caesarean section. METHODS: Women were randomised to receive 1 g IV, 1 g IM, 4 g oral TXA or no TXA. Adverse events in women and neonates were recorded. TXA concentration in whole blood was measured and the concentrations over time were examined with population pharmacokinetics. The relationship between drug exposure and D-dimer was explored. The trial registration is NCT04274335. MAIN OUTCOME MEASURES: Concentration of TXA in maternal blood. RESULTS: Of the 120 women included in the randomised safety study, there were no serious maternal or neonatal adverse events. TXA concentrations in 755 maternal blood and 87 cord blood samples were described by a two-compartment model with one effect compartment linked by rate transfer constants. Maximum maternal concentrations were 46.9, 21.6 and 18.1 mg/L for IV, IM and oral administration, respectively, and 9.5, 7.9 and 9.1 mg/L in the neonates. The TXA response was modelled as an inhibitory effect on the D-dimer production rate. The half-maximal inhibitory concentration (IC50 ) was 7.5 mg/L and was achieved after 2.6, 6.4 and 47 minutes with IV, IM and oral administration of TXA, respectively. CONCLUSIONS: Both IM and oral TXA are well tolerated. Oral TXA took about 1 hour to reach minimum therapeutic concentrations and would not be suitable for emergency treatment. Intramuscular TXA inhibits fibrinolysis within 10 minutes and may be a suitable alternative to IV.
Document Type: article in journal/newspaper
File Description: text
Language: English
ISSN: 1470-0328
Relation: https://researchonline.lshtm.ac.uk/id/eprint/4669756/1/ShakurStill-etal-2023-Alternative-routes-for-tranexamic-acid-treatment.pdf; Shakur-Still, Haleema ORCID logo; Roberts, Ian ORCID logo; Grassin-Delyle, Stanislas; Chaudhri, Rizwana; Geer, Amber ORCID logo; Arribas, Monica ORCID logo; Lamy, Elodie; Mansukhani, Raoul ORCID logo; Lubeya, Mwansa Ketty; Javaid, Kiran; +11 more.Kayani, Aasia; Israr, Naila; Mazhar, Syeda Batool; Urien, Saïk; Bouazza, Naïm; Foissac, Frantz; Prowse, Danielle; Carrington, Laura; Barrow, Collette; Onandia, Julio Gil ORCID logo; and Balogun, Eni ORCID logo (2023) Alternative routes for tranexamic acid treatment in obstetric bleeding (WOMAN-PharmacoTXA trial): a randomised trial and pharmacological study in caesarean section births. BJOG : an international journal of obstetrics and gynaecology, 130 (10). pp. 1177-1186. ISSN 1470-0328 DOI:10.1111/1471-0528.17455
DOI: 10.1111/1471-0528.17455
Availability: https://researchonline.lshtm.ac.uk/id/eprint/4669756/; https://doi.org/10.1111/1471-0528.17455
Rights: cc_by_4
Accession Number: edsbas.98FE927B
Database: BASE